Remedy Taking a hit why? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Technology Stocks : Remedy Taking a hit why?

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Lizzie Tudor who wrote (553)	5/12/1998 2:49:00 PM
From: Shege Dambanza	Read Replies (1) of 763

I don't think it's a short, but it is not a buy for me. The "non-essential" argument doesn't fly with me because it isn't all that expensive (< $30K for basic functionality for 5 users). If anything one could make a case that companies need to set up internal help desks (using Remedy et al) to support programmers working on Y2K conversions, and then users in Y2K. I think the bigger challenge facing Remedy is competition from many others--some big (NETA/McAfee/Vycor/Magic, IBM/Tivoli/SWRT) and some small (can't think of one off the top of my head)--which is driving down prices and margins. Remedy needs to leverage its ARS platform and develop CIS apps that sit on top of it e.g. SFA. Baystone is trying to do this, but they have challenges of their own. A new company called Nightingale is building apps for patient and work flow in clinics. Remedy needs to get into this value-added business for itself, or it is slowly going to fade into nothingness.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next